Glenmark opens antibody manufacturing facility in Switzerland

Glenmark Pharmaceuticals SA (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, has opened a cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. This manufacturing facility supplements Glenmark’s existing in-house discovery and development capabilities and will supply material for clinical development.
 
Glenmark Pharmaceuticals’ Swiss research centre is an integrated antibody discovery and development unit. The research centre has fully developed in-house capabilities and infrastructure for conducting antibody discovery, cell line development, in vitro testing and characterization of antibodies, process development and analytical research. The new manufacturing facility supplements the research and development capabilities and will facilitate production of clinical grade material.
 
The manufacturing facility has been designed for use of single use bioreactor systems and also houses a suite for manufacturing cell banks. The facility is fully compliant with quality, environmental and safety standards for manufacturing clinical trial material.
 
Dr Michael Buschle, President – Biologics, Glenmark Pharmaceuticals Ltd, commented, “This state of the art manufacturing facility is a testimony for Glenmark’s commitment to growing its R&D and manufacturing facility in the canton of Neuchatel. We have been doing cutting edge work in the area of novel monoclonal antibodies and have several monoclonal antibody candidates & bispecific antibodies in the pipeline. The manufacturing facility would help us bring these antibodies to the clinic faster and position Glenmark as a leading innovative pharmaceutical company.”